Target Name: ETNK1
NCBI ID: G55500
Review Report on ETNK1 Target / Biomarker Content of Review Report on ETNK1 Target / Biomarker
ETNK1
Other Name(s): ETNK1 variant 1 | Ethanolamine kinase 1, transcript variant 1 | Nbla10396 | EKI1 | EKI | EKI1_HUMAN | Ethanolamine kinase 1 isoform A | ATP:ethanolamine O-phosphotransferase | Putative protein product of Nbla10396 | EKI 1 | ETNK1 variant 2 | putative protein product of Nbla10396 | Ethanolamine kinase 1 isoform B | ethanolamine kinase 1 | Ethanolamine kinase 1 | Ethanolamine kinase 1, transcript variant 2

ETNK1: The drug target of interest

ETNK1, also known as ETNK1 variant 1, is a protein that is expressed in the brain and is known to play a critical role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and neurodegenerative diseases. In recent years, researchers have been increasingly interested in ETNK1 as a potential drug target, due to its unique structure and the potential impact it could have on treating these debilitating diseases.

The story of ETNK1 began in the late 1990s, when a team of researchers at the University of California, San Diego, identified a protein that was expressed in the brain and was involved in the formation of neurotransmitter receptors. This protein, known as ETNK1, was later shown to play a critical role in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Since then, researchers have continued to study ETNK1 and its role in the disease. They have found that ETNK1 is involved in the formation of dopamine receptors in the brain, and that its levels are often reduced in individuals with neurodegenerative diseases. They have also found that ETNK1 is involved in the regulation of the immune system, and that its levels are often increased in individuals with neurodegenerative diseases.

In addition to its role in the immune system, ETNK1 has also been shown to be involved in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. This is important because the blood-brain barrier is often broken in neurodegenerative diseases, and this can contribute to the development and progression of these diseases.

Despite the potential implications of ETNK1's role in the disease, much work remains to be done before it can be fully understood and used as a drug target. For example, researchers are still working to fully understand the exact mechanism by which ETNK1 contributes to the development and progression of neurodegenerative diseases. They are also working to develop techniques for targeting ETNK1 specifically, in order to avoid potential unintended consequences.

In addition to its potential use as a drug target, ETNK1 is also of interest as a biomarker for the diagnosis and monitoring of neurodegenerative diseases. For example, researchers have found that ETNK1 levels are often reduced in individuals with Alzheimer's disease, and that this can be used as a biomarker for the disease. They are also working to develop techniques for detecting ETNK1 levels in individuals with neurodegenerative diseases, which could potentially be used as a diagnostic tool.

Overall, ETNK1 is a protein that has captured the interest of researchers due to its unique structure and its potential role in the development and progression of various neurological disorders. While much work remains to be done before ETNK1 can be fully understood and used as a drug target, it is clear that it has the potential to make a significant impact on the treatment of these debilitating diseases.

Protein Name: Ethanolamine Kinase 1

Functions: Highly specific for ethanolamine phosphorylation. May be a rate-controlling step in phosphatidylethanolamine biosynthesis

The "ETNK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ETNK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ETNK2 | ETNPPL | ETS1 | ETS2 | ETS2-AS1 | ETV1 | ETV2 | ETV3 | ETV3L | ETV4 | ETV5 | ETV6 | ETV7 | Eukaryotic translation initiation factor 2-alpha kinase | Eukaryotic translation initiation factor 2B | Eukaryotic translation initiation factor 3 (eIF-3) complex | Eukaryotic Translation Initiation Factor 4A (eIF-4A) | Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2